These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22801854)

  • 1. Systemic and ocular risks associated with therapies for macular degeneration: clarification vs confusion.
    Friberg TR; Shah V; Bilonick RA
    Arch Ophthalmol; 2012 Jun; 130(6):806-7; author reply 807. PubMed ID: 22801854
    [No Abstract]   [Full Text] [Related]  

  • 2. Risks of adverse events with therapies for age-related macular degeneration: a response.
    Williams T; Reeves BC; Foss AJ; Fell G
    Arch Ophthalmol; 2012 Jan; 130(1):124-5; author reply 125-6. PubMed ID: 22232487
    [No Abstract]   [Full Text] [Related]  

  • 3. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration.
    Curtis LH; Hammill BG; Schulman KA; Cousins SW
    Arch Ophthalmol; 2010 Oct; 128(10):1273-9. PubMed ID: 20937996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273-1279.
    Wong D; Joussen AM
    Graefes Arch Clin Exp Ophthalmol; 2011 Feb; 249(2):161-2. PubMed ID: 21210141
    [No Abstract]   [Full Text] [Related]  

  • 5. Incidence of myocardial infarction, stroke, and death in patients with age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor therapy.
    Ng WY; Tan GS; Ong PG; Cheng CY; Cheung CY; Wong DW; Mathur R; Chow KY; Wong TY; Cheung GC
    Am J Ophthalmol; 2015 Mar; 159(3):557-64.e1. PubMed ID: 25497143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-macular degeneration agents.
    Rothen M; Jablon E; Monares G; Fontal MR; Alfaro DV
    Ophthalmol Clin North Am; 2005 Dec; 18(4):561-7. PubMed ID: 16314219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Photodynamic therapy in the anti-VEGF era.
    Fine HF
    Br J Ophthalmol; 2007 Jun; 91(6):707-8. PubMed ID: 17510474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.
    Nelson M
    Retina; 2010 Feb; 30(2):380; author reply 380-1. PubMed ID: 20142719
    [No Abstract]   [Full Text] [Related]  

  • 9. Ranibizumab and nonocular hemorrhage.
    Beaumont PE; Kang HK
    Ophthalmology; 2009 Aug; 116(8):1593. PubMed ID: 19651322
    [No Abstract]   [Full Text] [Related]  

  • 10. Estimating the potential impact of using intravitreal angiostatic agents for wet macular degeneration on service capacity in a large retinal referral centre.
    Cheung CM; Peh KK; Yang Y
    Eye (Lond); 2007 Aug; 21(8):1121-2. PubMed ID: 17525768
    [No Abstract]   [Full Text] [Related]  

  • 11. Review of combination therapies for neovascular age-related macular degeneration.
    Couch SM; Bakri SJ
    Semin Ophthalmol; 2011 May; 26(3):114-20. PubMed ID: 21609223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic therapy in neovascular age-related macular degeneration.
    Lin RC; Rosenfeld PJ
    Int Ophthalmol Clin; 2007; 47(1):117-37. PubMed ID: 17237677
    [No Abstract]   [Full Text] [Related]  

  • 13. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study.
    Sadda SR; Stoller G; Boyer DS; Blodi BA; Shapiro H; Ianchulev T
    Retina; 2010 Oct; 30(9):1390-9. PubMed ID: 20924261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration.
    Aggio FB; Melo GB; Höfling-Lima AL; Eid Farah M
    Acta Ophthalmol Scand; 2006 Dec; 84(6):831-3. PubMed ID: 17083553
    [No Abstract]   [Full Text] [Related]  

  • 15. Analysis of SERPING1 and its association with age-related macular degeneration.
    Carter JG; Churchill AJ
    Acta Ophthalmol; 2011 Mar; 89(2):e212-3. PubMed ID: 19925520
    [No Abstract]   [Full Text] [Related]  

  • 16. New perspectives on the treatment of age-related macular degeneration.
    Mones J
    Drugs Today (Barc); 2005 Nov; 41(11):701. PubMed ID: 16395410
    [No Abstract]   [Full Text] [Related]  

  • 17. Age-related macular degeneration and mortality from cardiovascular disease or stroke.
    Cackett P; Cheung N; Wong TY
    Br J Ophthalmol; 2008 Nov; 92(11):1564. PubMed ID: 18952662
    [No Abstract]   [Full Text] [Related]  

  • 18. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranibizumab for neovascular age-related macular degeneration.
    Gillies MC; Wong TY
    N Engl J Med; 2007 Feb; 356(7):748-9; author reply 749-50. PubMed ID: 17310523
    [No Abstract]   [Full Text] [Related]  

  • 20. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.
    Heier JS; Boyer DS; Ciulla TA; Ferrone PJ; Jumper JM; Gentile RC; Kotlovker D; Chung CY; Kim RY;
    Arch Ophthalmol; 2006 Nov; 124(11):1532-42. PubMed ID: 17101999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.